RU2017112747A - Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции - Google Patents

Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции Download PDF

Info

Publication number
RU2017112747A
RU2017112747A RU2017112747A RU2017112747A RU2017112747A RU 2017112747 A RU2017112747 A RU 2017112747A RU 2017112747 A RU2017112747 A RU 2017112747A RU 2017112747 A RU2017112747 A RU 2017112747A RU 2017112747 A RU2017112747 A RU 2017112747A
Authority
RU
Russia
Prior art keywords
quinidine
treatment
dementia
dextrometorphanic
demenium
Prior art date
Application number
RU2017112747A
Other languages
English (en)
Russian (ru)
Other versions
RU2017112747A3 (enExample
Inventor
Джоао СИФФЕРТ
Original Assignee
Аванир Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аванир Фармасьютикалз, Инк. filed Critical Аванир Фармасьютикалз, Инк.
Publication of RU2017112747A publication Critical patent/RU2017112747A/ru
Publication of RU2017112747A3 publication Critical patent/RU2017112747A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/49Cinchonan derivatives, e.g. quinine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22Bridged ring systems
    • C07D221/28Morphinans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2017112747A 2014-09-14 2015-09-14 Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции RU2017112747A (ru)

Applications Claiming Priority (35)

Application Number Priority Date Filing Date Title
US201462050170P 2014-09-14 2014-09-14
US62/050,170 2014-09-14
US201462061451P 2014-10-08 2014-10-08
US62/061,451 2014-10-08
US201462063122P 2014-10-13 2014-10-13
US62/063,122 2014-10-13
US201462063861P 2014-10-14 2014-10-14
US62/063,861 2014-10-14
US201462068742P 2014-10-26 2014-10-26
US62/068,742 2014-10-26
US201562111053P 2015-02-02 2015-02-02
US62/111,053 2015-02-02
US201562111590P 2015-02-03 2015-02-03
US62/111,590 2015-02-03
US201562128446P 2015-03-04 2015-03-04
US62/128,446 2015-03-04
US201562162140P 2015-05-15 2015-05-15
US62/162,140 2015-05-15
US201562165535P 2015-05-22 2015-05-22
US62/165,535 2015-05-22
US201562169997P 2015-06-02 2015-06-02
US62/169,997 2015-06-02
US201562180026P 2015-06-15 2015-06-15
US62/180,026 2015-06-15
US201562193347P 2015-07-16 2015-07-16
US62/193,347 2015-07-16
US201562205061P 2015-08-14 2015-08-14
US62/205,061 2015-08-14
US201562216636P 2015-09-10 2015-09-10
US62/216,636 2015-09-10
US201562217142P 2015-09-11 2015-09-11
US201562217470P 2015-09-11 2015-09-11
US62/217,142 2015-09-11
US62/217,470 2015-09-11
PCT/US2015/049934 WO2016040930A1 (en) 2014-09-14 2015-09-14 Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2020116666A Division RU2838188C2 (ru) 2014-09-14 2020-05-21 Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции

Publications (2)

Publication Number Publication Date
RU2017112747A true RU2017112747A (ru) 2018-10-15
RU2017112747A3 RU2017112747A3 (enExample) 2019-04-29

Family

ID=55459653

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017112747A RU2017112747A (ru) 2014-09-14 2015-09-14 Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции

Country Status (15)

Country Link
US (3) US20190111047A1 (enExample)
EP (4) EP3932907A3 (enExample)
JP (4) JP2017531033A (enExample)
KR (1) KR20170052684A (enExample)
CN (3) CN107072990A (enExample)
AU (3) AU2015314710A1 (enExample)
CA (1) CA2960031A1 (enExample)
IL (2) IL250786A0 (enExample)
MX (3) MX2017003066A (enExample)
MY (1) MY198587A (enExample)
PH (1) PH12017500444A1 (enExample)
RU (1) RU2017112747A (enExample)
SG (2) SG11201701645WA (enExample)
TW (3) TW202106301A (enExample)
WO (1) WO2016040930A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3208128A1 (en) 2007-05-01 2008-11-13 Sun Pharmaceutical Industries, Inc. Morphinan compounds
US20180243291A1 (en) * 2015-07-30 2018-08-30 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for treating agitation
WO2017020002A1 (en) * 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
WO2018009488A1 (en) * 2016-07-04 2018-01-11 Avanir Pharmaceuticals, Inc. Methods for the synthesis of deuterated dextromethorphan
RU2760558C9 (ru) * 2017-05-04 2022-02-22 Эксива Гмбх Целевой лекарственный препарат и новые композиции, комбинации на его основе и способы их применения
US11478467B2 (en) 2017-05-04 2022-10-25 Sreenivasarao Vepachedu Targeted drug rescue with novel compositions, combinations, and methods thereof
EP3794345B1 (en) * 2018-05-18 2025-02-26 Anavex Life Sciences Corp. Optimized sigma-1 agonist method of responder selection and treatment
CA3126062C (en) * 2019-01-07 2024-02-06 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
PH12021552266A1 (en) * 2019-03-18 2022-07-11 Avanir Pharmaceuticals Inc Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
CA3176234A1 (en) * 2020-04-27 2021-11-04 Sanjay Dube Methods of treating agitation associated with alzheimer's disease
WO2022228363A1 (zh) * 2021-04-27 2022-11-03 杭州剂泰医药科技有限责任公司 一种组合物的医药用途
CN115322150B (zh) * 2021-05-11 2024-05-28 深圳信立泰药业股份有限公司 氘代右美沙芬氢溴酸盐的固体及其制备方法和医药用途
CN113209042A (zh) * 2021-05-28 2021-08-06 珠海润都制药股份有限公司 一种氢溴酸右美沙芬硫酸奎尼丁胶囊及其制备方法
KR20240110812A (ko) * 2021-10-27 2024-07-16 아바니르 파마슈티컬스, 인코포레이티드 알츠하이머병과 관련된 불안을 치료하는 방법
CN116459255A (zh) * 2022-01-19 2023-07-21 深圳信立泰药业股份有限公司 氘代右美沙芬与安非他酮联合在制备ad激越的药物中的用途
US11730706B1 (en) * 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
KR20250120917A (ko) 2024-02-02 2025-08-11 단국대학교 천안캠퍼스 산학협력단 덱스트로메토르판을 유효성분으로 포함하는 신경 질환 예방 또는 치료용 약학 조성물
KR20250129211A (ko) 2024-02-22 2025-08-29 단국대학교 천안캠퍼스 산학협력단 데가렐릭스를 유효성분으로 포함하는 신경 질환 예방 또는 치료용 약학적 조성물

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5166207A (en) 1991-06-17 1992-11-24 Neurotherapeutics, Inc. Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
US5366980A (en) 1991-06-17 1994-11-22 Smith Richard A Use of dextromethorphan and an oxidase inhibitor to treat dermatitis
US5206248A (en) 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
US5350756A (en) 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
TW264473B (enExample) * 1993-01-06 1995-12-01 Hoffmann La Roche
WO1996009044A1 (en) * 1994-09-22 1996-03-28 Richard Alan Smith Compositions useful for the preparation of medicines for treating a variety of intractable disorders
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
WO1999026614A1 (en) 1997-11-21 1999-06-03 Euro-Celtique S.A. Substituted 2-aminoacetamides and the use thereof
WO1999050245A1 (en) 1998-03-26 1999-10-07 Shionogi & Co., Ltd. Indole derivatives with antiviral activity
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
AU2007212586A1 (en) * 2006-02-03 2007-08-16 Avanir Pharmaceuticals Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders
WO2007103474A2 (en) * 2006-03-07 2007-09-13 University Of Florida Research Foundation, Inc. Drug adherence monitoring system
WO2008097924A2 (en) * 2007-02-05 2008-08-14 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
EP2345653B1 (en) * 2007-05-01 2012-12-26 Concert Pharmaceuticals Inc. Morphinan compounds
CA3208128A1 (en) * 2007-05-01 2008-11-13 Sun Pharmaceutical Industries, Inc. Morphinan compounds
EA030882B1 (ru) * 2008-09-19 2018-10-31 Консерт Фармасьютикалз Инк. Дейтерированные морфинановые соединения и их применение
HUE028956T2 (en) * 2008-10-30 2017-01-30 Concert Pharmaceuticals Inc Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect
KR101649332B1 (ko) * 2008-11-14 2016-08-18 콘서트 파마슈티컬즈, 인크. 치환된 다이옥소피페리디닐 프탈이미드 유도체
CA3154845C (en) * 2013-11-05 2023-02-28 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds and dextromethorphan

Also Published As

Publication number Publication date
MX2022008181A (es) 2022-08-10
EP3708168A2 (en) 2020-09-16
AU2022283671A1 (en) 2023-02-02
TW201613591A (en) 2016-04-16
US20190111047A1 (en) 2019-04-18
CN117427077A (zh) 2024-01-23
RU2020116666A (ru) 2020-07-31
EP3932907A2 (en) 2022-01-05
RU2017112747A3 (enExample) 2019-04-29
EP3193872A1 (en) 2017-07-26
AU2020289733A1 (en) 2021-01-21
US20200289499A1 (en) 2020-09-17
JP2023105265A (ja) 2023-07-28
WO2016040930A1 (en) 2016-03-17
EP3193872A4 (en) 2018-02-28
PH12017500444A1 (en) 2017-07-31
TW202231278A (zh) 2022-08-16
SG11201701645WA (en) 2017-04-27
MX2017003066A (es) 2017-09-12
CN107072990A (zh) 2017-08-18
MY198587A (en) 2023-09-06
CA2960031A1 (en) 2016-03-17
US20240082237A1 (en) 2024-03-14
EP3932907A3 (en) 2022-03-30
EP3708168A3 (en) 2020-12-09
SG10201901242PA (en) 2019-03-28
CN110664801A (zh) 2020-01-10
KR20170052684A (ko) 2017-05-12
JP2020019818A (ja) 2020-02-06
MX2021010696A (es) 2021-10-01
TW202106301A (zh) 2021-02-16
TWI869633B (zh) 2025-01-11
IL274742A (en) 2020-07-30
JP2017531033A (ja) 2017-10-19
JP7360409B2 (ja) 2023-10-12
IL250786A0 (en) 2017-04-30
AU2015314710A1 (en) 2017-04-20
JP2021080300A (ja) 2021-05-27
EP4166141A1 (en) 2023-04-19
AU2022283671B2 (en) 2025-03-20

Similar Documents

Publication Publication Date Title
RU2017112747A (ru) Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции
MX2024010140A (es) Nuevos metodos.
JP2017075173A5 (enExample)
ME02910B (me) Spojevi tetrahidropirolotiazina
EA201490774A1 (ru) Новые производные оксазина и их применение при лечении заболевания
WO2016065226A8 (en) Indole carboxamides compounds useful as kinase inhibitors
EA201791199A1 (ru) Способ лечения болезни альцгеймера
EA201791872A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
EA201491773A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата
EA201790305A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE
RU2017105353A (ru) Соединения
JP2016510326A5 (enExample)
EA201691789A1 (ru) Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты
EA201991387A1 (ru) ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
CY1124115T1 (el) Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
RU2019110980A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
JP2015516419A5 (enExample)
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
RU2016112257A (ru) Композиция для лечения гипертензии и/или фиброза
EP2802319A4 (en) FESTDOSIS COMBINATION THERAPY OF MORBUS PARKINSON
EA201590687A1 (ru) Лечение легкой и умеренной болезни альцгеймера
RU2020120876A (ru) Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200730